240 related articles for article (PubMed ID: 37194481)
1. Antipsychotics and obsessive-compulsive disorder/obsessive-compulsive symptoms: A pharmacovigilance study of the FDA adverse event reporting system.
Burk BG; DiGiacomo T; Polancich S; Pruett BS; Sivaraman S; Birur B
Acta Psychiatr Scand; 2023 Jul; 148(1):32-46. PubMed ID: 37194481
[TBL] [Abstract][Full Text] [Related]
2. Quetiapine and obsessive-compulsive symptoms (OCS): case report and review of atypical antipsychotic-induced OCS.
Khullar A; Chue P; Tibbo P
J Psychiatry Neurosci; 2001 Jan; 26(1):55-9. PubMed ID: 11212595
[TBL] [Abstract][Full Text] [Related]
3. Weight gain, gender, and antipsychotics: a disproportionality analysis of the FDA Adverse Event Reporting System database (FAERS).
Stamoula E; Stamatellos VP; Vavilis T; Dardalas I; Papazisis G
Expert Opin Drug Saf; 2024 Feb; 23(2):239-245. PubMed ID: 37589503
[TBL] [Abstract][Full Text] [Related]
4. A pharmacovigilance study of the association between antipsychotic drugs and venous thromboembolism based on Food and Drug Administration Adverse Event Reporting System data.
Yan Y; Wang L; Yuan Y; Xu J; Chen Y; Wu B
Expert Opin Drug Saf; 2024 Jun; 23(6):771-776. PubMed ID: 37615268
[TBL] [Abstract][Full Text] [Related]
5. Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study.
Cepaityte D; Siafis S; Egberts T; Leucht S; Kouvelas D; Papazisis G
Schizophr Bull; 2021 Apr; 47(3):672-681. PubMed ID: 33289848
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of adverse reactions among antipsychotic drugs using the Korean Adverse Event Reporting System database from 2010 to 2019.
Oh S; Byeon SJ; Chung SJ
J Psychopharmacol; 2022 Sep; 36(9):1041-1050. PubMed ID: 35695641
[TBL] [Abstract][Full Text] [Related]
7. Safety of antipsychotic drugs: A systematic review of disproportionality analysis studies.
Cepaityte D; Siafis S; Papazisis G
Behav Brain Res; 2021 Apr; 404():113168. PubMed ID: 33581145
[TBL] [Abstract][Full Text] [Related]
8. Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
Fusaroli M; Raschi E; Giunchi V; Menchetti M; Rimondini Giorgini R; De Ponti F; Poluzzi E
Int J Neuropsychopharmacol; 2022 Sep; 25(9):727-736. PubMed ID: 35639870
[TBL] [Abstract][Full Text] [Related]
9. Induced Obsessive Compulsive Symptoms (OCS) in schizophrenia patients under Atypical 2 Antipsychotics (AAPs): review and hypotheses.
Grillault Laroche D; Gaillard A
Psychiatry Res; 2016 Dec; 246():119-128. PubMed ID: 27690134
[TBL] [Abstract][Full Text] [Related]
10. Clozapine-Associated Obsessive-Compulsive Symptoms and Their Management: A Systematic Review and Analysis of 107 Reported Cases.
Kim DD; Barr AM; Lu C; Stewart SE; White RF; Honer WG; Procyshyn RM
Psychother Psychosom; 2020; 89(3):151-160. PubMed ID: 32045914
[TBL] [Abstract][Full Text] [Related]
11. Obsessive-compulsive symptoms in patients with schizophrenia: a naturalistic cross-sectional study comparing treatment with clozapine, olanzapine, risperidone, and no antipsychotics in 543 patients.
Scheltema Beduin AA; Swets M; Machielsen M; Korver N;
J Clin Psychiatry; 2012 Nov; 73(11):1395-402. PubMed ID: 23218156
[TBL] [Abstract][Full Text] [Related]
12. Psychopharmacotherapy of Obsessive-Compulsive Symptoms within the Framework of Tourette Syndrome.
Rothenberger A; Roessner V
Curr Neuropharmacol; 2019; 17(8):703-709. PubMed ID: 30152283
[TBL] [Abstract][Full Text] [Related]
13. Aripiprazole-induced obsessive-compulsive symptoms.
Nafisa D; Kakunje A
Ind Psychiatry J; 2022; 31(1):158-161. PubMed ID: 35800864
[TBL] [Abstract][Full Text] [Related]
14. [Obsessive-Compulsive Symptoms in a Sample of Patients with Chronic Schizophrenia Under Clozapine Treatment].
Schreiter S; Hasan A; Majic T; Wullschleger A; Schouler-Ocak M; Bermpohl F; Gutwinski S
Fortschr Neurol Psychiatr; 2016 Nov; 84(11):675-681. PubMed ID: 27846652
[No Abstract] [Full Text] [Related]
15. Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review.
Sareen J; Kirshner A; Lander M; Kjernisted KD; Eleff MK; Reiss JP
J Affect Disord; 2004 Oct; 82(2):167-74. PubMed ID: 15488245
[TBL] [Abstract][Full Text] [Related]
16. Antiserotonergic antipsychotics are associated with obsessive-compulsive symptoms in schizophrenia.
Schirmbeck F; Esslinger C; Rausch F; Englisch S; Meyer-Lindenberg A; Zink M
Psychol Med; 2011 Nov; 41(11):2361-73. PubMed ID: 21466748
[TBL] [Abstract][Full Text] [Related]
17. Antipsychotics-associated serious adverse events in children: an analysis of the FAERS database.
Kimura G; Kadoyama K; Brown JB; Nakamura T; Miki I; Nisiguchi K; Sakaeda T; Okuno Y
Int J Med Sci; 2015; 12(2):135-40. PubMed ID: 25589889
[TBL] [Abstract][Full Text] [Related]
18. Second generation antipsychotic-induced obsessive-compulsive symptoms in schizophrenia: a review of the experimental literature.
Fonseka TM; Richter MA; Müller DJ
Curr Psychiatry Rep; 2014 Nov; 16(11):510. PubMed ID: 25256097
[TBL] [Abstract][Full Text] [Related]
19. Drug-induced parkinsonism: Revisiting the epidemiology using the WHO pharmacovigilance database.
de Germay S; Montastruc F; Carvajal A; Lapeyre-Mestre M; Montastruc JL
Parkinsonism Relat Disord; 2020 Jan; 70():55-59. PubMed ID: 31865063
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
